期刊文献+

鲑鱼降钙素影响骨质疏松患者血清胰岛素样生长因子、白介素6和肿瘤坏死因子α的临床观察 被引量:8

Clinical observation of the effect of miacalcic on the serum IGF-1,IL-6 and TNF-α in patients with osteoporosis
下载PDF
导出
摘要 目的研究鲑鱼降钙素对骨质疏松患者骨密度和体内细胞因子的影响。方法将本院60例骨质疏松患者随机分成两组,对照组30例口服钙尔奇D 1片/天,观察组30例在对照组治疗方案基础上加用鲑鱼降钙素。治疗前后检测两组患者第2-4腰椎和股骨颈骨密度(Bone mineral density,BMD)、胰岛素样生长因子-1(Insulin-like growth factor-1,IGF-1)、血清白细胞介素6(Interleukin-6,IL-6)、肿瘤坏死因子α(Tumor necrosis factor-α,TNF-α)的变化,观察患者临床症状的改善。结果 (1)观察组第2-4腰椎和股骨颈BMD升高较对照组明显(P<0.05);(2)观察组患者IGF-1、IL-6以及TNF-α水平明显低于对照组(P<0.01);(3)观察组患者骨痛改善率高于对照组(P<0.05)。(4)无论治疗组还是对照组的BMD均与IGF-1呈正相关,与IL-6和TNF-α呈负相关。结论鲑鱼降钙素可有效提升骨质疏松患者腰椎和股骨颈BMD,并能够改善IGF-1、IL-6以及TNF-α水平,有效缓解疼痛。 Objective To evaluate the effect of miacalcic on bone mineral density(BMD) and cytokines in the osteoporotic patients.Methods Sixty patients with osteoporosis were equally randomly assigned into 2 groups.Patients in control group(30cases) received 600 mg Caltrate per day.Patients in observation group(30 cases) received miacalcic besides Caltrate.The BMD of L2-4 lumbar spine and the femoral neck,insulin-like growth factor-1(IGF-1),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α) were determined before and after the treatment.Clinical symptoms were observed.Results BMD of the L2-4 lumbar spine and the femoral neck were higher in observation group than in control group(P 0.05).The serum levels of IGF-1,IL-6,and TNF-α were lower in observation group than in control group(P 0.01).Pain was significantly relieved in the treatment group compared to control group(P 0.05).BMD change was positively correlated to IGF-1 but negatively correlated to IL-6 and TNF-α in both groups.Conclusion Miacalcic is effective to improve BMD and to relieve pain in patients with osteoporosis.It can improve the levels of IGF-1,IL-6,and TNF-α.It can effectively relieve pain.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2014年第10期1230-1232,1239,共4页 Chinese Journal of Osteoporosis
关键词 骨质疏松 IGF-1 IL-6 TNF-α 鲑鱼降钙素 Osteoporosis IGF-1 IL-6 TNF-α Miacalcic
  • 相关文献

参考文献10

  • 1Dawson-Hughes B, Looker AC, Tosteson AN, et al. The potential impact of the national osteoporosis foundation guidance on treatment eligibility in the USA: An update in nhanes 2005- 2008, Osteoporos Int, 2012, 23 : 811-820.
  • 2Yakar S, Rosen C J, Beamer WG, et al. Circulating levels of igf- 1 directly regulate bone growth and density. J Clin Invest, 2002, 110:771-781.
  • 3Kwan Tat S, Padrines M, Theoleyre S, et al. II-6, rankl, tnf- alpha/il-l: Interrelations in bone resorption pathophysiology. Cytokine & growth factor reviews ,2004,15:49-60.
  • 4Devlin RD, Reddy SV, Savino R, et al. I1-6 mediates the effects of il-I or tnf, but not pthrp or 1,25 (oh) 2d3, on osteoclast-like cell formation in normal human bone marrow cultures. ] Bone Miner Res, 1998,13:393-399.
  • 5Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis : The prevent recurrence of osteoporotic fractures study. Proof study group. Am J Med,2000,109:267-276.
  • 6Inada M, Miyaura C. Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis. Clinical calcium, 2010,20: 1467- 1472.
  • 7Teitelbaum SL. Postmenopausal osteoporosis, t cells, and immune dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2004 101: 16711- 16712.
  • 8Cranney A, Tugwelt P, Zytaruk N, et al, The Osteoporosis Research Advisory G. Meta-analyses of therapies for postmenopausal osteoporosis. Vi. Meta-analysis of ealcitonin for the treatment of postmenopausal osteoporosis. Endocrine Reviews, 2002, 23:540-551.
  • 9Cardona JM, Pastor E. Caleitohin versus etidronate for the treatment of postmenopausal osteoporosis: A recta-analysis of published clinical trials. Osteoporos Int, 1997, 7:165-174.
  • 10Kaji K, Katogi R, Azuma Y, et al. Tumor necrosis factor alpha- induced osteoclastogenesis requires tumor necrosis factor receptor- associated factor 6. J Bone Miner Res, 2001,16 : 1593-1599.

同被引文献85

  • 1Drake MT, Khosla S. Male osteoporosis[J]. Endocrinol Metab Clin North Am, 2012, 41(3):629-641.
  • 2Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013[J]. Maturitas, 2013, 75(4):392-396.
  • 3lki M, Tamaki J, Fujita Y, et al. Serum undercarboxylated osteoealein levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study[J]. Osteoporos Int, 2012, 23(2):761-770.
  • 4Redmond J, Palla L, Yan L, et al. Ethnic differences in urinary calcium and phosphate excretion between Gambian and British older adults[J]. Osteoporos Int, 2015, 26(3): 1125-1135.
  • 5Verschueren S, Gielen E, O'Neill TW, et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men[J]. Osteoporos Int, 2013, 24(1):87-98.
  • 6Bhandari KH, Asghar W, Newa M, et al. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis[J]. Curr Drug Deliv, 2015, 12(1):98-107.
  • 7Cosman F, De Beur S J, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis[J]. Osteoporos Int, 2014, 25(10):2359-2381.
  • 8Bhandari KH, Newa M, Chapman J, et al. Synthesis, charac- terization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats[J]. J Control Release, 2012, 158(1):44-52.
  • 9李西海,梁文娜,刘献祥.从痰瘀论治膝骨性关节炎50例临床观察[J].中医杂志,2009,50(2):136-138. 被引量:33
  • 10原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. 被引量:1833

引证文献8

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部